STAT+: Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk
Biotech veteran Jeremy Levin discusses the future of the biotech industry and the challenges it faces. He highlights the importance of maintaining public trust and strong institutions to support scientific advancements. Levin calls for federal changes to incentivize investment in biotech and emphasizes the need for industry leaders to speak out against regulatory issues.
- ▪Jeremy Levin is the founder and chairman of Ovid Therapeutics and former CEO of Teva Pharmaceuticals.
- ▪In his book, Levin argues that political upheaval and weakening institutions are putting the future of biotech at risk.
- ▪He advocates for federal changes to incentivize biotech investment and for companies to address regulatory challenges.
STAT News files mainly under health. We currently carry 214 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | STAT |
| Canonical URL | https://www.statnews.com/2026/05/28/biotech-veteran-jeremey-levin-on-why-the-industrys-future-is-secure-but-american-leadership-is-at-risk/?utm_campaign=rss |
| Publication time | Thu, 28 May 2026 18:48:50 +0000 |
| Retrieval time | 2026-05-28T18:54:43.020Z |
| Last seen | 2026-05-28T19:01:29.349Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | yLsWQmF77Mfh |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Biotech veteran Jeremey Levin on why the industry’s future is secure, but American leadership is at risk In an interview, the longtime executive explains how the field can persevere in a time of distrust Manage alerts for this article Email this article Share this article Jeremy Levin speaks at a STAT eventGreg Riccardi for STAT By Adam Feuerstein, Allison DeAngelis, and Elaine ChenMay 28, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at STAT.
Discussion
0 commentsMore from STAT
